Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) (A2697-GRP)
Products
Description
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2697 |
| Target | CD markers |